ArticleThe oncologist2026
Molecular and immune correlates of lymphocyte activation gene-3 expression in renal cell carcinoma.
Article in The oncologist, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLymphocyte activation gene-3 (LAG-3) is an immune checkpoint receptor that has emerged as a biomarker of interest but its relationship with outcomes in renal cell carcinoma (RCC) is poorly characterized. This study evaluates molecular and immune correlates of LAG-3 expression and its association with outcomes.
methodsDe-identified DNA-NGS data (xT) and RNA-NGS (xR) from patients (pts) with RCC (n = 566) within the Tempus multi-modal database were analyzed using Lens. Eligible pts had first-line (1 L) immunotherapy (IO) and biopsies collected within 1 year of IO. Samples were stratified into 4 quartiles by LAG-3 RNA expression (TPM). Immune cell proportions were estimated from RNA (quanTIseq). Real-world objective response rate (rwORR) was assessed within 90 days of IO. Real-world overall survival (rwOS), defined as time from 1 L IO start to death, lost to follow-up, or 5 years after 1 L, was analyzed using Cox proportional hazard models and P-values (Wald test).
resultsThe median age was 61 and majority were male (72%), white (79%), with metastases at specimen collection (94%). BAP1 (P = .008) and NF2 (P = .015) were increased in the highest LAG-3 groups, while VHL, PBMR1, and SETD2 were not. LAG-3 correlated with higher CTLA4, PD1, PD-L1, PD-2, TIM3, and TIGIT RNA expression (all P < .001), and increased M1/M2 macrophages, NK, B, CD8 T, and Treg cell % (all P < .001). Higher LAG-3 expression was associated with improved rwORR and lower disease progression (P = .039). rwOS was not statistically significant (P = .2).
conclusionsLAG-3 is associated with distinct tumor immune features and may serve as a biomarker for early IO response in RCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.